Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexagliflozin placebo-controlled phase 3 study in type 2 diabetes with increased cardiovascular risk
2015-001760-19Phase 3Completed
- Sponsor
- Theracos, Inc.
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Bexagliflozin with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Primary efficacy hypothesis. Started Sep 2015; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-001760-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001760-19.